Sponsor content

Oxford BioMedica, a leader in gene and cell therapies

With its unique LentiVector platform and expanding state-of-the-art manufacturing facilities, Oxford BioMedica has established itself as the partner of choice for companies developing advanced therapy medicinal products. To download the full article, please sign in.

Go to the profile of Oxford BioMedica
Nov 10, 2015
1
Upvote 1
Page of
Go to the profile of Oxford BioMedica

Oxford BioMedica

A newfound confidence has entered the fields of gene and cell therapy, and biopharmaceutical company Oxford BioMedica has had an important role in the development of these transformative therapeutic areas. The company, based in Oxford, has 20 years of experience in developing lentivirus-based vectors, and its pioneering platform technologies underpin the design, development and manufacture of a portfolio of gene- and cell-based medicines. Its expanding manufacturing capabilities, in-house know-how and intellectual property (IP) have attracted the attention of leading players in the field, with the company recently entering into a major collaboration with Novartis to develop chimeric antigen receptor (CAR) T cell therapeutics. Oxford BioMedica has been building its geneand cell-therapy platform since 1995, when it was spun out of the University of Oxford’s Department of Biochemistry by Alan and Susan Kingsman. An initial public offering on the Alternative Investment Market followed a year later, with a move to the main London Stock Exchange in 2001. With a growing research program and development pipeline, Oxford BioMedica has been continuously expanding—thanks to a substantial increase in size during 2014 and 2015, the company now has more than 210 employees. Oxford BioMedica boasts its own world-class Centre of Excellence in process development and manufacturing services for lentiviral vectors, coupled with a totally integrated supply chain.

Comments are disabled